| CAS NO: | 216227-54-2 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 216227-54-2 |
| 别名 | OC 144-093; OC 144093 |
| Canonical SMILES | CCOC/C=C/C1=CC=C(C2=NC(C3=CC=C(NC(C)C)C=C3)=C(C4=CC=C(NC(C)C)C=C4)N2)C=C1 |
| 分子式 | C32H38N4O |
| 分子量 | 494.7 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ONT-093 is an orally bioavailable substituted diarylimidazole inhibitor of P-glycoprotein ATPase activity (IC50 = 0.16 μM).1 It reverses drug resistance to doxorubicin , vinblastine , and paclitaxel in human lymphoma, breast, ovarian, uterine, and colorectal cancer cell lines in vitro (EC50s = 9-38 nM). It is not cytotoxic to 15 normal, non-transformed, or tumor cell lines when used at concentrations up to 100 μM and exhibits weak cytostatic activity (average IC50 = >60 μM). ONT-093 (30 mg/kg) reverses paclitaxel drug resistance in an HCT15 human colon carcinoma mouse xenograft model. |1. Newman, M.J., Rodarte, J.C., Benbatoul, K.D., et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 60(11), 2964-2972 (2000). |
m.cnreagent.com